Outcomes in COVID-19 mefenamic acid studies

All studies   Hospitalization   Serious outcomes   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -189% 1 36 Improvement, Studies, Patients Relative Risk Hospitalization -189% 1 36 RCTs -189% 1 36 Early -189% 1 36 Mefenamic Acid for COVID-19 c19early.org November 2025 Favorsmefenamic acid Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MEFECOVID-19 Guzman‑.. (DB RCT) -189% 2.89 [0.13-66.7] hosp. 1/19 0/17 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Early treatment -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk All studies -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk 1 mefenamic acid COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors mefenamic acid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MEFECOVID-19 Guzman‑.. (DB RCT) -189% 2.89 [0.13-66.7] hosp. 1/19 0/17 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Early treatment -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk All studies -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk 1 mefenamic acid COVID-19 hospitalization result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Favors mefenamic acid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MEFECOVID-19 Guzman‑.. (DB RCT) -189% 2.89 [0.13-66.7] hosp. 1/19 0/17 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Early treatment -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk All studies -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk 1 mefenamic acid COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors mefenamic acid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MEFECOVID-19 Guzman‑.. (DB RCT) -189% 2.89 [0.13-66.7] hosp. 1/19 0/17 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Early treatment -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk All studies -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk 1 mefenamic acid COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors mefenamic acid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MEFECOVID-19 Guzman‑.. (DB RCT) -189% 2.89 [0.13-66.7] hosp. 1/19 0/17 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Early treatment -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk All studies -189% 2.89 [0.13-66.7] 1/19 0/17 189% higher risk 1 mefenamic acid COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Effect extraction pre-specified(most serious outcome) Favors mefenamic acid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MEFECOVID-19 Guzman‑.. (DB RCT) -189% 2.89 [0.13-66.7] hosp. 1/19 0/17 Improvement, RR [CI] Treatment Control Mefenamic acid COVID-19 outcomes c19early.org November 2025 Favors mefenamic acid Favors control